Background and Aims

CGM is increasingly used to improve glucose monitoring in newborns at risk of fluctuating glucose levels, particularly hypoglycaemia, such as preterm infants, infants born to mothers with diabetes, and babies who are small or large for gestational age. Although, safety and effectiveness of the newest generation of CGM for people with diabetes ages 2 and up is well known, there is no evidence in newborns.

Aim of our study is to evaluate accuracy of the newest generation of CGM (Dexcom G6) in newborns of diabetic mother.

Methods

11 newborns of diabetic mother were recruited and monitored by CGM for the first 48 h of life. Blood glucose levels (SMBG) were performed at least every four hours. We calculated the difference between CGM and SMBG values, at the times of the capillary sample.

Results

The percentage difference was less than 12% considering all the values. The difference was reduced to 8% for values > 3.89 mmol/L and increased to 12% for values between 2.78 to 3.89 mmol/l. For values below 2.78 mmol/L the difference was of 14%.

Conclusions

The newest generation of CGM (Dexcom G6) could be use in newborns, especially in infants of diabetic mother who needs frequent blood sugar checks. Good correlation between SGMB and CGM values makes their use possible in neonatal intensive care. Further studies are needed to determinate the accuracy of Dexcom G6 in newborn.